Investigation of Antimicrobial and Antitubercular Activities of Some Hydrazone Derived Compounds

Abstract

A series of hydrazone derivatives were synthesized to investigate antifungal, antimicrobial and antitubercular activities. These activities were investigated against Escherichia coli, Escherichia coli isolate, Pseudomonas aeruginosa, Pseudomonas aeruginosa isolate (resistant to gentamicin), Staphylococcus aureus, Staphylococcus aureus isolate (MRSA), Enterococcus faecalis, Enterococcus faecalis isolate (VRE), Candida albicans, Candida krusei and Mycobacterium tuberculosis. Among the synthesized compounds B23 had the best activity against Candida albicans with 16 µg/mL MIC value and B24 had the best activity against Staphylococcus aureus isolate (MRSA) with 16 µg/mL MIC value. The most effective compound against Mycobacterium tuberculosis is found to be E9 with 32 µg/mL MIC value, a chalcone derivative. However, all compounds were determined as ineffective against Escherichia coli and Escherichia coli isolate.

Keywords

• Hydrazone,Antitubercular activity,Antimicrobial activity

Bazı Hidrazon Türevi Bileşiklerin Antimikrobiyal ve Antitüberküler Etkilerinin Araştırılması

Abstract

Bir seri hidrazon türevi, antifungal, antimikrobiyal ve antitüberküler etkilerini araştırmak için sentezlendi. Bileşiklerin bu etkileri, Escherichia coli, Escherichia coli izolat (ESBL), Pseudomonas aeruginosa, Pseudomonas aeruginosa izolat (gentamisine dirençli), Staphylococcus aureus, Staphylococcus aureus izolat (MRSA), Enterococcus faecalis, Enterococcus faecalis izolat (VRE), Candida albicans, Candida krusei ve Mycobacterium tuberculosis karşısında araştırıldı. Sentez edilen bileşiklerden B23 Candida albicans karşısında 16 µg/mL MİK değeri ile, B24 ise Staphylococcus aureus izolatı (MRSA) karşısında 16 µg/mL MİK değeri ile en iyi etkiyi gösterdi. Mycobacterium tuberculosis karşısında en etkin bileşiğin ise 32 µg/mL MİK değeri ile bir şalkon türevi olan E9 olduğu bulundu. Bununla birlikte, tüm bileşiklerin Escherichia coli ve Escherichia coli isolat karşısında etkisiz olduğu saptandı.

Keywords

• Hidrazon,Antitüberküler etki,Antimikrobiyal etki

References

1. [1] Tiberi, S., Plessis, N., Walzl, G., Vjecha, M. J., Rao, M., Ntoumi, F., Mfinanga, S., Kapata, N., Mvaba, P., McHugh, T. D., Ippolito, G., Migliori, G. B., Maeurer, M. J., Zumla, A. 2018. Tuberculosis: progress and advances in development of new drugs, treatment regimens and host-directed therapies. Lancet Infectious Disease. 18(7), e183-e198.
2. [2] Furin, J., Cox, H., Pai, M. 2019. Tuberculosis. Lancet, 393, 1642-1656.
3. [3] Evranos-Aksöz, B. 2014. New Drug candidates in tuberculosis treatment. Turkish Bulletin of Hygiene and Experimental Biology, 71(4), 207-220.
4. [4] WHO. 2017. Global tuberculosis report, 2017. Geneva World Health Organization, https://reliefweb.int/report/world/global-tuberculosis-report-2017 (Accessed date: 03.01.2020)
5. [5] Monedero, I., Caminero, J. A. 2010. Management of multidrug-resistant tuberculosis: an update. Therapeutic Advances in Respiratory Disease, 4, 117-127.
6. [6] Yao, L., LiangLiang, C., JinYue, L., WanMei, S., Lili, S., YiFan, L., HuaiChen, L. 2019. Ambient air pollution exposures and risk of drug-resistant tuberculosis. Environment International, 124, 161-169.
7. [7] Tong, S. Y., Davis, J. S., Eichenberger, E., Holland, T. L., Fowler, V.G. 2015. Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management. Clinical Microbiology Reviews, 28(3), 603-661.
8. [8] Rasigade, J. P., Vandenesch, F. 2014. Staphylococcus aureus: a pathogen with still unresolved issues. Infection Genetic Evolution, 21, 510-514.

9. [9] Sancak, B. 2011. Staphylococcus aureus and antibiotic resistance. Bulletin of Microbiology, 45(3), 565-576.
10. [10] Bradley, S. F. 2002. Staphylococcus aureus infections and antibiotic resistance in older adults. Clinical Infectious Diseases, 34, 211-216.
11. [11] Xu, M., Wu, P., Shen, F., Ji, J., Rakesh, K. P. 2019. Chalcone derivatives and their antibacterial activities: current development. Bioorganic Chemistry, 91, 103-133.
12. [12] Çetinkaya Şardan, Y. MRSA as a causative agent of nosocomial infection: prevention and control. İchastaliklaridergisi.org/managete/fu_folder/2007-03/html/2007-14-3-161-167.htm (Accessed date: 15.12.2019).
13. [13] Thomer, L., Schneewind, O., Missiakas, D. 2016. Pathogenesis of Staphylococcus aureus bloodstream infections. Annual Review of Pathology, 11, 343-364.
14. [14] Lowy F. D. 1998. Staphylococcus aureus infections. The New England Journal of Medicine, 20, 339(8), 520-532.
15. [15] Sardi, J. C. O., Scorzoni, L., Bernardi, T., Fusco-Almeida, A. M., Mendes Giannini, M. J. S. 2013. Candida species: current epidemiology, pathogenicity, biofilm formation, natural antifungal products and new therapeutic options. Journal of Medical Microbiology, 62, 10-24.
16. [16] Rollas, S., Küçükgüzel, Ş.G. 2007. Biological activities of hydrazone derivatives. Molecules, 12, 1910-1939.
17. [17] Popiolek, L. 2017. Hydrazide – hydrazones as potential antimicrobial agents: overview of the literature since 2010. Medicinal Chemistry Research, 26, 287-301.
18. [18] Nasrullaev, A., Bozorov, K., Bobakulov, K., Zhao, J., Nie, L. F., Turgunov, K. K., Elmuradov, B., Aisa, H. A. 2019. Synthesis, characterization, and antimicrobial activity of novel hydrazone‑bearing tricyclic quinazolines. Research on Chemical Intermediates, 45, 2287-2300.
19. [19] Evranos-Aksoz, B., Baysal, I., Yabanoglu-Ciftci, S., Djikic, T., Yelekci, K., Ucar, G., Ertan, R. 2015. Synthesis and screening of human monoamine oxidase-A inhibitor effect of new 2-pyrazoline and hydrazone derivatives. Archive Der Pharmazie, 348, 743-756.
20. [20] Clinical and Laboratory Standards Institute (CLSI) (formerly NCCLS). 2006a. Performance standards for antimicrobial susceptibility testing 6th informational supplement. CLSI M100-S16, Clinical and Laboratory Standards Institute, 940 West Valley Road, Wayne, Pennsylvania, USA.
21. [21] Clinical and Laboratory Standards Institute (CLSI) (formerly NCCLS). 2006b. Reference method for broth dilution antifungal susceptibility testing of yeast approved standard, M27-A, Clinical and Laboratory Standards Institute, 940 West Valley Road, Wayne, Pennsylvania, USA.
22. [22] Evranos-Aksöz, B., Onurdağ, F. K., Özgacar, S. Ö. 2015. Antibacterial, antifungal and antimycobacterial activities of some pyrazoline, hydrazone and chalcone derivatives. Zeitschrift für Naturforschung C, 70(7-8), 183-189.
23. [23] Franzblau, S. G., Witzig, R. S., McLaughlin, J. C., Torres, P., Madico, G., Hernandez, A., Degnan, M.T., Cook, M. B., Quenzer, V.K., Ferguson, R.M., Gilman, R.H. 1998. Rapid, low-technology MIC determination with clinical Mycobacterium tuberculosis isolates by using the microplate alamar blue assay. Journal of Clinical Microbiology, 36, 362–366.